[
  {
    "ts": "2025-10-08T14:22:18+00:00",
    "headline": "Cramer’s ‘Absolute Favorite’ AbbVie Rises After Study Completions and Upgrade",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of Jim Cramer’s Recession-Proof Stock Picks. Cramer calls the stock his ‘absolute favorite,’ and it is followed by updates on the completion of two key studies. At the beginning of this month, AbbVie Inc. (NYSE:ABBV) announced the completion of a key study on ABBV-101’s food interaction and a Phase 2 […]",
    "url": "https://finance.yahoo.com/news/cramer-absolute-favorite-abbvie-rises-142218944.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "89d1e3bf-75c0-308a-839f-98f141e88e68",
      "content": {
        "id": "89d1e3bf-75c0-308a-839f-98f141e88e68",
        "contentType": "STORY",
        "title": "Cramer’s ‘Absolute Favorite’ AbbVie Rises After Study Completions and Upgrade",
        "description": "",
        "summary": "AbbVie Inc. (NYSE:ABBV) is one of Jim Cramer’s Recession-Proof Stock Picks. Cramer calls the stock his ‘absolute favorite,’ and it is followed by updates on the completion of two key studies. At the beginning of this month, AbbVie Inc. (NYSE:ABBV) announced the completion of a key study on ABBV-101’s food interaction and a Phase 2 […]",
        "pubDate": "2025-10-08T14:22:18Z",
        "displayTime": "2025-10-08T14:22:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Cramer’s ‘Absolute Favorite’ AbbVie Rises After Study Completions and Upgrade",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aXAa28AvezyRv056g_RUEg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lzVMSqWRbEKelBHS4c050A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cramer-absolute-favorite-abbvie-rises-142218944.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cramer-absolute-favorite-abbvie-rises-142218944.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-08T14:03:56+00:00",
    "headline": "AbbVie Inc. (ABBV) Starts Building $70 Million Expansion of Its AbbVie Bioresearch Centre in Worcester, Massachusetts",
    "summary": "With significant hedge fund interest and trending on Reddit, AbbVie Inc. (NYSE:ABBV) secures a spot on our list of the 10 Best Non-Tech Stocks to Buy According to Reddit. As part of its $10 billion U.S. capital expenditure strategy to increase biologics manufacturing capacity, AbbVie Inc. (NYSE:ABBV) started building a $70 million expansion of its […]",
    "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-starts-building-140356446.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "2b802fcc-c5c8-3635-a3d5-d0f0cc00e5b2",
      "content": {
        "id": "2b802fcc-c5c8-3635-a3d5-d0f0cc00e5b2",
        "contentType": "STORY",
        "title": "AbbVie Inc. (ABBV) Starts Building $70 Million Expansion of Its AbbVie Bioresearch Centre in Worcester, Massachusetts",
        "description": "",
        "summary": "With significant hedge fund interest and trending on Reddit, AbbVie Inc. (NYSE:ABBV) secures a spot on our list of the 10 Best Non-Tech Stocks to Buy According to Reddit. As part of its $10 billion U.S. capital expenditure strategy to increase biologics manufacturing capacity, AbbVie Inc. (NYSE:ABBV) started building a $70 million expansion of its […]",
        "pubDate": "2025-10-08T14:03:56Z",
        "displayTime": "2025-10-08T14:03:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/05c9701ec29e5502e16f87177f12c553",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "AbbVie Inc. (ABBV) Starts Building $70 Million Expansion of Its AbbVie Bioresearch Centre in Worcester, Massachusetts",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yBdl8vPZu4vOEW46gz40vA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/05c9701ec29e5502e16f87177f12c553.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RbXAAj3VuxBo0SkvsQQL1w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/05c9701ec29e5502e16f87177f12c553.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-starts-building-140356446.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-starts-building-140356446.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-08T07:41:35+00:00",
    "headline": "Why AbbVie Stock Soared in September",
    "summary": "It was a month stuffed with several different kinds of wins for the pharmaceutical company.",
    "url": "https://www.fool.com/investing/2025/10/08/why-abbvie-stock-soared-in-september/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "cee67166-c2fb-3f5f-b6c5-09ec3b6b3177",
      "content": {
        "id": "cee67166-c2fb-3f5f-b6c5-09ec3b6b3177",
        "contentType": "STORY",
        "title": "Why AbbVie Stock Soared in September",
        "description": "",
        "summary": "It was a month stuffed with several different kinds of wins for the pharmaceutical company.",
        "pubDate": "2025-10-08T07:41:35Z",
        "displayTime": "2025-10-08T07:41:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/401d48140fec27f7f06795be7a163be9",
          "originalWidth": 1400,
          "originalHeight": 935,
          "caption": "Person checking medicine on a shelf in a pharmacy.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zwBIMU8YliGanN.S.jD0Pg--~B/aD05MzU7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/401d48140fec27f7f06795be7a163be9.cf.webp",
              "width": 1400,
              "height": 935,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eZjcMxRoPE3jqlH3lG4xaA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/401d48140fec27f7f06795be7a163be9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/08/why-abbvie-stock-soared-in-september/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-abbvie-stock-soared-september-074135283.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]